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The consumption of designer drugs today is a serious problem, especially among young 
people involvement. ‘Herbal mixtures’ containing synthetic cannabinoids (SCs) that mimic 
the effect of marijuana and there are easily available via the Internet. For analysis of urine 
samples, knowledge of the main metabolites is necessary as the mother compounds are 
usually not found in urine after using, due to their fast metabolism. The aims of this study 
were the in vitro identification of metabolites of ADB-FUBINACA, 5F-MDMB-PICA and 
CUMYL-PEGACLONE and to determine which analytical targets are excreted into urine. 
Metabolites identified after incubation of SCs with pooled human liver microsomes (HLM). 
The authentic urine samples were analysed by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) for investigation of the major in vivo metabolites. The main 
metabolites were the mono-hydroxylation of ADB-FUBINACA and CUMYL-PEGACLONE 
in positive urine specimens. We didn’t have positive sample of 5F-MDMB-PICA. 
 
Introduction 
Synthetic cannabinoids are a group of designer drugs that mimic and magnify natural 
cannabinoids effect. The CB1 and CB2 cannabinoid receptor agonists SCs sold as ‘herbal 
smoking mixtures’ are promoted as legal alternative to marijuana, to circumvent drug 
scheduling legislation [1]. The SCs are highly potent and responsible for many acute 
intoxications and deaths [2, 3]. In forensic practice the SC consumption is detecting the parent 
molecules in urine and blood specimens. Due to their fast metabolism prior the renal 
extraction, in most cases the parent compounds are detectable in narrow time window in 
human urine. The present study aims to identify appropriate marker metabolites by 
investigating of phase I metabolism of ADB-FUBINACA as a most commonly used SC, 5F-
MDMB-PICA and CUMYL-PEGACLONE as the newest SCs (Figure 1), using pooled 
human liver microsome (HLM), and to confirm the results in authentic human urine samples.  
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Figure 1 Chemical structure of ADB-FUBINACA (A), 5F-MDMB-PICA (B) and CUMYL-
PEGACLONE (C) synthetic cannabinoids 
 
Experimental 
The LC-MS/MS method and the new sample preparation was developed for identification and 
analysis of metabolites in HLM and urine samples. The SCs was incubated with HLM at 37°C 
for 30 min. The urine samples were analysed after β-glucuronidase hydrolysis. The analysis 
was performed on a Q Exactive Plus hybrid quadrupole-Orbitrap mass spectrometer (Thermo 
Fisher Scientific, Waltham, MA, USA) coupled with a Waters Acquity I-Class UPLC™ 
(Waters, Manchester, UK). Compound separation was achieved using a Kinetex C18 column 
(150 x 2.1 mm, 2.6 µm, Phenomenex, Torrance, CA, USA) combined with a guard column 
maintained at 50°C at a constant flow rate of 0.4 mL/min. Mobile phase A consisted of 0.1% 
formic acid, and mobile phase B was acetonitrile with 0.1% formic acid. The HLM incubates 
and urine samples were analyzed in positive electrospray ionization (ESI) mode. The mass 
spectrometer was operated in full scan and parallel reaction monitoring acquisition (PRM) 
modes. 
 
Results and discussion 
The developed analytical LC-MS/MS method provided the separation and characterization of 
numerous ADB-FUBINACA, 5F-MDMB-PICA and CUMYL-PEGACLONE phase I 
metabolites.  
7 phase I metabolites of ADB-FUBINACA were detected in authentic urine sample (Table 1). 
The identified metabolites were assigned to 5 different biotransformations, including amide 
hydrolysis, dehydrogenation, monohydroxylation, formation of carbonyl derivatives and their 
isomers. The main metabolite of ADB-FUBINACA was the aliphatic mono-hydroxylated 
(M4) form [4].  
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Amide hydrolysis + 
dehydrogenation 
C21H20N3O3F 13.74 382.1561 


































Amide hydrolysis + 
aliphatic hydroxylation 




















For 5F-MDMB-PICA (Fig. 2), 13 phase I metabolites were identified by accurate m/z values 
and the fragmentation behaviour known from the literature [5].  
 
 
Figure 2 Extracted ion chromatogram of identified metabolits of 5F-MDMB-PICA in HLM 
The new analytical method provided over 35 phase I metabolites of CUMYL-PEGACLONE 
in authentic urine specimens, such as formation of dehydrogenation, mono- and di-
hydroxilation, dealkylation, carbonylation and carboxylation and their isomers. Fig. 3 shows 
Extracted ion chromatogram of human liver microsome
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the MS/MS spectra of three di-hydroxilated metabolites of CUMYL-PEGACLONE. The 
biotransformation site on the structure of the molecule was determined by characteristic 
fragment ions. The mono-hydroxylated metabolite (M45) was identified as specific and 
sensitive urinary markers to proof consumption of CUMYL-PEGACLONE [6]. 
 
 




The present study describes the identification of phase I metabolites of ADB-FUBINACA, 
5F-MDMB-PICA and CUMYL-PEGACLONE after incubation with pooled human liver 
microsomes. The main metabolite of ADB-FUBINACA and CUMYL-PEGACLONE was 
formation of mono-hydroxylation in authentic urine specimens.  
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